AE Clinical Biology SRL

AE Clinical Biology reported total assets of 273,294 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Jun 2026).

Company number (CBE) 1003.340.185
1410 Waterloo
active in Manufacture of basic pharmaceutical products (NACE 21100)
operating since 13 Dec 2023 (≈ 3 yrs)
Public Public page: latest year only. The score, history and details open with a free account. Create a free account
Idonis solidity score
EDCBA

The score of AE Clinical Biology shows with a free account.

See the score
Profile
SRL since 2023
Components
  • Summary? / 5
    • Balance sheet strength
    • Liquidity
    • Repayment capacity
    • Profitability
    • Trajectory
    • Compliance and register
  • Position in its sectorvs peers
  • Supplier creditat 30 d
  • Borrowing capacityborrowable
  • Valuationcentral

Visible once signed in: create your account, the 14-day Pro trial is free.

Detail

Key figures 2025

Net result109,632 €
Equity51,518 €
Cash23,945 €
EBITDA143,003 €
Total assets273,294 €
The line marks its sector median: 38.7% (82 companies).

Change 2023 → 2025: Equity +91 % Total assets +227 %

Accounts of the company itself (not consolidated).

The full file covers 3 financial years; a free account shows 2. →

Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error

AE Clinical Biology's annual accounts

202520242023
Net result109,632 €
Equity51,518 €
Cash23,945 €
EBITDA143,003 €
Total assets273,294 €

Filed annual accounts

  • Year ended 31 Dec 2025filed on 30 Jun 2026
  • Year ended 31 Dec 2024filed on 03 Jul 2025
  • Year ended 31 Dec 2023filed on 19 Aug 2024

AE Clinical Biology's financial analysis

Management and control of AE Clinical Biology

2 active director(s) in the register.

AE Clinical Biology's shareholders and holdings →

AE Clinical Biology's publications in the Belgian Gazette

Company number, VAT number and registered office

Company number (CBE)
1003.340.185
VAT number
No VAT activity declared to the CBE
Peppol
Registered · 0208:1003340185 · as of 10 Nov 2026
Legal form
SRL
Incorporated
13 Dec 2023
Registered office
1410 Waterloo
Latest accounts
2025 · filed on 30 Jun 2026
Activity
Manufacture of basic pharmaceutical products (NACE 21100)

AE Clinical Biology (SRL) has been based in Waterloo since 2023, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net profit of 109,632 € and equity of 51,518 €; its revenue is not published.

Guide: Reading Belgian SME accounts: the five figures that count →

Companies similar to AE Clinical Biology

Companies in the same business, of comparable size and area, outside its group.

Frequently asked questions about AE Clinical Biology

What is the revenue of AE Clinical Biology?

AE Clinical Biology files its accounts in a format where revenue is optional: it is not published for 2025.

What is the VAT number of AE Clinical Biology?

According to the Crossroads Bank for Enterprises, no VAT-liable activity is declared for AE Clinical Biology. If it is VAT-registered, its VAT number is its company number prefixed with BE: BE1003340185. Its company number (CBE) is 1003.340.185.

Where is the registered office of AE Clinical Biology?

According to the CBE register, the registered office of AE Clinical Biology is in 1410 Waterloo.

What is the equity of AE Clinical Biology?

At the close of the 2025 financial year, the equity of AE Clinical Biology amounts to 51,518 €, a solvency of 18.9% of total assets.

Who manages AE Clinical Biology?

The register lists 2 active mandates at AE Clinical Biology. Names and roles are in the full file, with the deeds published in the Belgian Gazette.

Idonis

The full file of AE Clinical Biology

Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.

Open the full file →
Free account in 30 seconds, by email. No bank card.
Sources : Annual accounts — NBB ↗ Register — CBE ↗ Deeds — Belgian Gazette ↗ · Updated on 22 Sep 2026

No credit card, no commitment.

What each plan unlocks →